Literature DB >> 29414763

Production of lipid mediators across different disease stages of dextran sodium sulfate-induced colitis in mice.

Taiki Hamabata1, Tatsuro Nakamura1, Sakura Masuko1, Shingo Maeda1, Takahisa Murata2.   

Abstract

Although several studies have revealed the role of different lipid mediators in colitis, the comprehensive analysis of their production across different phases of colitis remained unclear. Here, we performed the following analysis in the dextran sodium sulfate (DSS)-induced colitis model using LC-MS/MS. Oral administration of 2% DSS in mice for 4 days resulted in severe intestinal inflammation by day 7, which gradually subsided by day 18. Based on the disease scoring index (assigned on the basis of fecal condition and weight loss), we defined the phases of colitis as induction (days 0-4), acute inflammation (days 4-7), recovery (days 7-9), and late recovery (days 9-18). Across all phases, 58 lipid mediators were detected in the inflamed colon tissue. In the induction phase, the production of n-6 fatty acid-derived prostaglandin E2 and thromboxane B2 increased by ∼2-fold. In the acute inflammation phase, the production of n-6 fatty acid-derived leukotrienes increased by >10-fold, while that of n-3 fatty acid-derived hydroxyeicosapentaenoic acids and dihydroxyeicosatetraenoic acids decreased. In the recovery phase, a precursor of protectin D1 (17-hydroxydocosahexaenoic acid) increased over 3-fold. These observations suggested dynamic changes in the production of lipid mediators across different phases of the disease and their potential regulation in healing colitis.
Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  arachidonic acid; cyclooxygenase; inflammation; lipidomics; lipoxygenase; omega-3 fatty acids

Mesh:

Substances:

Year:  2018        PMID: 29414763      PMCID: PMC5880491          DOI: 10.1194/jlr.M079095

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  33 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.

Authors:  H Tozaki; T Fujita; T Odoriba; A Terabe; T Suzuki; C Tanaka; S Okabe; S Muranishi; A Yamamoto
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

3.  A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.

Authors:  Stefano Fiorucci; John L Wallace; Andrea Mencarelli; Eleonora Distrutti; Giovanni Rizzo; Silvana Farneti; Antonio Morelli; Jih-Lie Tseng; Babu Suramanyam; William J Guilford; John F Parkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

4.  The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.

Authors:  Yasser El Miedany; Sally Youssef; Ihab Ahmed; Maha El Gaafary
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

5.  Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.

Authors:  X Bertrán; J Mañé; F Fernández-Bañares; E Castellá; R Bartolí; I Ojanguren; M Esteve; M A Gassull
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

6.  Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+.

Authors:  Mikhail Strokin; Marina Sergeeva; Georg Reiser
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

7.  Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.

Authors:  B J R Whittle; C Varga; A Berko; K Horvath; A Posa; J P Riley; K A Lundeen; A M Fourie; P J Dunford
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

Review 8.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

9.  Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis.

Authors:  Yasuyuki Deguchi; Akira Andoh; Osamu Inatomi; Yuhki Yagi; Shigeki Bamba; Yoshio Araki; Kazunori Hata; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

10.  The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis.

Authors:  Amir F Sheibanie; Jui-Hung Yen; Tanzilya Khayrullina; Frances Emig; Ming Zhang; Ronald Tuma; Doina Ganea
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

View more
  8 in total

1.  Calcium/calmodulin-dependent protein kinase IV (CaMKIV) activation contributes to the pathogenesis of experimental colitis via inhibition of intestinal epithelial cell proliferation.

Authors:  Kellie E Cunningham; Elizabeth A Novak; Garret Vincent; Vei Shaun Siow; Brian D Griffith; Sarangarajan Ranganathan; Matthew R Rosengart; Jon D Piganelli; Kevin P Mollen
Journal:  FASEB J       Date:  2018-08-16       Impact factor: 5.191

2.  5,6-DiHETE attenuates vascular hyperpermeability by inhibiting Ca2+ elevation in endothelial cells.

Authors:  Taiki Hamabata; Tatsuro Nakamura; Yuri Tachibana; Daiki Horikami; Takahisa Murata
Journal:  J Lipid Res       Date:  2018-08-03       Impact factor: 5.922

Review 3.  The complex role of prostaglandin E2-EP receptor signaling in wound healing.

Authors:  Kristy E Gilman; Kirsten H Limesand
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-12-09       Impact factor: 3.619

Review 4.  Fatty acid metabolism in the host and commensal bacteria for the control of intestinal immune responses and diseases.

Authors:  Koji Hosomi; Hiroshi Kiyono; Jun Kunisawa
Journal:  Gut Microbes       Date:  2019-05-23

5.  Involvement of Proinflammatory Arachidonic Acid (ARA) Derivatives in Crohn's Disease (CD) and Ulcerative Colitis (UC).

Authors:  Justyna Kikut; Małgorzata Mokrzycka; Arleta Drozd; Urszula Grzybowska-Chlebowczyk; Maciej Ziętek; Małgorzata Szczuko
Journal:  J Clin Med       Date:  2022-03-27       Impact factor: 4.241

6.  Frondanol, a Nutraceutical Extract from Cucumaria frondosa, Attenuates Colonic Inflammation in a DSS-Induced Colitis Model in Mice.

Authors:  Sandeep B Subramanya; Sanjana Chandran; Saeeda Almarzooqi; Vishnu Raj; Aisha Salem Al Zahmi; Radeya Ahmed Al Katheeri; Samira Ali Al Zadjali; Peter D Collin; Thomas E Adrian
Journal:  Mar Drugs       Date:  2018-04-30       Impact factor: 5.118

Review 7.  The Role of Long-Chain Fatty Acids in Inflammatory Bowel Disease.

Authors:  Chunxiang Ma; Reshma Vasu; Hu Zhang
Journal:  Mediators Inflamm       Date:  2019-11-03       Impact factor: 4.711

8.  Clostridium butyricum MIYAIRI 588-Induced Protectin D1 Has an Anti-inflammatory Effect on Antibiotic-Induced Intestinal Disorder.

Authors:  Tadashi Ariyoshi; Mao Hagihara; Shuhei Eguchi; Aiki Fukuda; Kenta Iwasaki; Kentaro Oka; Motomichi Takahashi; Yuka Yamagishi; Hiroshige Mikamo
Journal:  Front Microbiol       Date:  2020-10-30       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.